Analysis of P-glycoprotein expression in osteosarcoma

M. Serra, K. Scotlandi, M. C. Manara, D. Maurici, S. Benini, M. Sarti, M. Campanacci, N. Baldini

Research output: Contribution to journalArticle

Abstract

Current treatment of high-grade osteosarcoma combines surgical removal of the lesion with chemotherapy. In this study we evaluated whether the expression of P-glycoprotein, a protein closely associated with multidrug resistance, may be helpful in identifying the patients whose tumours will be further resistant to specific agents. By using multidrug-resistant osteosarcoma cell lines as standards, the expression of P-glycoprotein was evaluated in 105 cases of primary and metastatic osteosarcoma by semiquantitative immunofluorescence. Overexpression of the protein was shown in 23% of primary and in 50% of metastatic lesions. In 38 cases, homogeneously treated and followed-up for at least 24 months, overexpression of P-glycoprotein appeared to be associated with a higher relapse rate and with a trend toward a worse outcome. These data support the role of P-glycoprotein in the response to chemotherapy and its involvement in the determination of the outcome of osteosarcoma patients.

Original languageEnglish
Pages (from-to)1998-2002
Number of pages5
JournalEuropean Journal of Cancer
Volume31
Issue number12
DOIs
Publication statusPublished - 1995

Fingerprint

P-Glycoprotein
Osteosarcoma
Drug Therapy
Multiple Drug Resistance
Fluorescent Antibody Technique
Proteins
Recurrence
Cell Line
Neoplasms
Therapeutics

Keywords

  • chemotherapy
  • immunofluorescence
  • multidrug resistance
  • osteosarcoma
  • P-glycoprotein

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Hematology

Cite this

Analysis of P-glycoprotein expression in osteosarcoma. / Serra, M.; Scotlandi, K.; Manara, M. C.; Maurici, D.; Benini, S.; Sarti, M.; Campanacci, M.; Baldini, N.

In: European Journal of Cancer, Vol. 31, No. 12, 1995, p. 1998-2002.

Research output: Contribution to journalArticle

@article{d79e982b64954b1d90d7425199369d47,
title = "Analysis of P-glycoprotein expression in osteosarcoma",
abstract = "Current treatment of high-grade osteosarcoma combines surgical removal of the lesion with chemotherapy. In this study we evaluated whether the expression of P-glycoprotein, a protein closely associated with multidrug resistance, may be helpful in identifying the patients whose tumours will be further resistant to specific agents. By using multidrug-resistant osteosarcoma cell lines as standards, the expression of P-glycoprotein was evaluated in 105 cases of primary and metastatic osteosarcoma by semiquantitative immunofluorescence. Overexpression of the protein was shown in 23{\%} of primary and in 50{\%} of metastatic lesions. In 38 cases, homogeneously treated and followed-up for at least 24 months, overexpression of P-glycoprotein appeared to be associated with a higher relapse rate and with a trend toward a worse outcome. These data support the role of P-glycoprotein in the response to chemotherapy and its involvement in the determination of the outcome of osteosarcoma patients.",
keywords = "chemotherapy, immunofluorescence, multidrug resistance, osteosarcoma, P-glycoprotein",
author = "M. Serra and K. Scotlandi and Manara, {M. C.} and D. Maurici and S. Benini and M. Sarti and M. Campanacci and N. Baldini",
year = "1995",
doi = "10.1016/0959-8049(95)00335-5",
language = "English",
volume = "31",
pages = "1998--2002",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "12",

}

TY - JOUR

T1 - Analysis of P-glycoprotein expression in osteosarcoma

AU - Serra, M.

AU - Scotlandi, K.

AU - Manara, M. C.

AU - Maurici, D.

AU - Benini, S.

AU - Sarti, M.

AU - Campanacci, M.

AU - Baldini, N.

PY - 1995

Y1 - 1995

N2 - Current treatment of high-grade osteosarcoma combines surgical removal of the lesion with chemotherapy. In this study we evaluated whether the expression of P-glycoprotein, a protein closely associated with multidrug resistance, may be helpful in identifying the patients whose tumours will be further resistant to specific agents. By using multidrug-resistant osteosarcoma cell lines as standards, the expression of P-glycoprotein was evaluated in 105 cases of primary and metastatic osteosarcoma by semiquantitative immunofluorescence. Overexpression of the protein was shown in 23% of primary and in 50% of metastatic lesions. In 38 cases, homogeneously treated and followed-up for at least 24 months, overexpression of P-glycoprotein appeared to be associated with a higher relapse rate and with a trend toward a worse outcome. These data support the role of P-glycoprotein in the response to chemotherapy and its involvement in the determination of the outcome of osteosarcoma patients.

AB - Current treatment of high-grade osteosarcoma combines surgical removal of the lesion with chemotherapy. In this study we evaluated whether the expression of P-glycoprotein, a protein closely associated with multidrug resistance, may be helpful in identifying the patients whose tumours will be further resistant to specific agents. By using multidrug-resistant osteosarcoma cell lines as standards, the expression of P-glycoprotein was evaluated in 105 cases of primary and metastatic osteosarcoma by semiquantitative immunofluorescence. Overexpression of the protein was shown in 23% of primary and in 50% of metastatic lesions. In 38 cases, homogeneously treated and followed-up for at least 24 months, overexpression of P-glycoprotein appeared to be associated with a higher relapse rate and with a trend toward a worse outcome. These data support the role of P-glycoprotein in the response to chemotherapy and its involvement in the determination of the outcome of osteosarcoma patients.

KW - chemotherapy

KW - immunofluorescence

KW - multidrug resistance

KW - osteosarcoma

KW - P-glycoprotein

UR - http://www.scopus.com/inward/record.url?scp=0029564659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029564659&partnerID=8YFLogxK

U2 - 10.1016/0959-8049(95)00335-5

DO - 10.1016/0959-8049(95)00335-5

M3 - Article

C2 - 8562155

AN - SCOPUS:0029564659

VL - 31

SP - 1998

EP - 2002

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 12

ER -